Gsk Plc-spon Adr. (GSK)

$33.7

+0.35

(+1.05%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $33.18
    $33.70
    $33.70
    downward going graph

    1.54%

    Downside

    Day's Volatility :1.54%

    Upside

    0.0%

    downward going graph
  • $32.83
    $45.93
    $33.70
    downward going graph

    2.6%

    Downside

    52 Weeks Volatility :28.52%

    Upside

    26.62%

    downward going graph

Returns

PeriodGsk Plc-spon Adr.Russel 2000Index (Russel 2000)
3 Months
-19.67%
0.0%
0.0%
6 Months
-26.39%
0.0%
0.0%
1 Year
-4.26%
0.0%
0.0%
3 Years
-34.71%
-24.1%
-24.1%

Highlights

Market Capitalization
68.0B
Book Value
$3.43
Dividend Share
0.61
Dividend Yield
4.69%
Earnings Per Share (EPS)
1.54
PE Ratio
21.66
PEG Ratio
0.71
Wall Street Target Price
45.946
Profit Margin
8.02%
Operating Margin TTM
8.33%
Return On Assets TTM
7.24%
Return On Equity TTM
21.85%
Revenue TTM
31.3B
Revenue Per Share TTM
15.38
Quarterly Revenue Growth YOY
-1.7000000000000002%
Gross Profit TTM
19.9B
EBITDA
9.3B
Diluted Eps TTM
1.54
Quarterly Earnings Growth YOY
-0.28
EPS Estimate Current Year
3.95
EPS Estimate Next Year
4.28
EPS Estimate Current Quarter
1.23
EPS Estimate Next Quarter
0.58

Analyst Recommendation

Buy
    60%Buy
    30%Hold
    9%Sell
Based on 33 Wall street analysts offering stock ratings for Gsk Plc-spon Adr.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
19
18
Hold
10
10
12
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 36.34%

Current $33.70
Target $45.95

Company Financials

FY18Y/Y Change
Revenue
39.0B
↑ 2.1%
Net Income
4.6B
↑ 136.49%
Net Profit Margin
11.75%
↑ 6.67%
FY19Y/Y Change
Revenue
44.2B
↑ 9.52%
Net Income
6.1B
↑ 28.21%
Net Profit Margin
13.76%
↑ 2.01%
FY20Y/Y Change
Revenue
45.8B
↑ 1.02%
Net Income
7.7B
↑ 23.77%
Net Profit Margin
16.86%
↑ 3.1%
FY21Y/Y Change
Revenue
45.4B
↑ 0.04%
Net Income
5.8B
↓ 23.73%
Net Profit Margin
12.85%
↓ 4.01%
FY22Y/Y Change
Revenue
35.7B
↓ 14.04%
Net Income
18.2B
↑ 241.07%
Net Profit Margin
51.0%
↑ 38.15%
FY23Y/Y Change
Revenue
38.4B
↑ 3.42%
Net Income
6.2B
↓ 67.05%
Net Profit Margin
16.25%
↓ 34.75%
Q2 FY23Q/Q Change
Revenue
10.3B
↑ 17.21%
Net Income
1.8B
↓ 1.74%
Net Profit Margin
17.97%
↓ 3.47%
Q3 FY23Q/Q Change
Revenue
10.0B
↓ 1.17%
Net Income
434.4M
↓ 76.09%
Net Profit Margin
4.35%
↓ 13.62%
Q4 FY23Q/Q Change
Revenue
9.3B
↓ 8.56%
Net Income
1.3B
↑ 198.86%
Net Profit Margin
14.21%
↑ 9.86%
Q1 FY24Q/Q Change
Revenue
10.0B
↑ 7.08%
Net Income
1.5B
↑ 12.14%
Net Profit Margin
14.88%
↑ 0.67%
Q2 FY24Q/Q Change
Revenue
10.2B
↑ 1.62%
Net Income
-73.7M
↓ 104.94%
Net Profit Margin
-0.72%
↓ 15.6%
Q3 FY24Q/Q Change
Revenue
8.0B
↑ 0.0%
Net Income
-58.0M
↑ 0.0%
Net Profit Margin
-0.72%
↑ 0.0%
FY18Y/Y Change
Total Assets
73.5B
↑ 2.99%
Total Liabilities
68.9B
↑ 2.84%
FY19Y/Y Change
Total Assets
104.3B
↑ 37.24%
Total Liabilities
80.3B
↑ 12.76%
FY20Y/Y Change
Total Assets
108.0B
↑ 0.93%
Total Liabilities
80.1B
↓ 2.79%
FY21Y/Y Change
Total Assets
105.2B
↓ 1.65%
Total Liabilities
76.8B
↓ 3.12%
FY22Y/Y Change
Total Assets
73.2B
↓ 23.96%
Total Liabilities
60.9B
↓ 13.35%
FY23Y/Y Change
Total Assets
74.7B
↓ 1.9%
Total Liabilities
58.5B
↓ 7.67%
Q2 FY23Q/Q Change
Total Assets
76.9B
↑ 3.87%
Total Liabilities
60.9B
↑ 2.03%
Q3 FY23Q/Q Change
Total Assets
73.2B
↓ 3.05%
Total Liabilities
57.4B
↓ 4.21%
Q4 FY23Q/Q Change
Total Assets
74.1B
↓ 0.84%
Total Liabilities
57.3B
↓ 2.01%
Q1 FY24Q/Q Change
Total Assets
73.8B
↓ 0.76%
Total Liabilities
56.3B
↓ 2.18%
Q2 FY24Q/Q Change
Total Assets
73.8B
↓ 0.03%
Total Liabilities
56.7B
↑ 0.68%
Q3 FY24Q/Q Change
Total Assets
58.0B
↑ 0.0%
Total Liabilities
44.6B
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
10.7B
↑ 21.73%
Investing Cash Flow
-2.0B
↑ 7.62%
Financing Cash Flow
-8.1B
↑ 0.14%
FY19Y/Y Change
Operating Cash Flow
10.5B
↓ 4.76%
Investing Cash Flow
-7.0B
↑ 244.75%
Financing Cash Flow
-2.4B
↓ 71.2%
FY20Y/Y Change
Operating Cash Flow
11.3B
↑ 5.25%
Investing Cash Flow
2.9B
↓ 140.36%
Financing Cash Flow
-13.6B
↑ 450.65%
FY21Y/Y Change
Operating Cash Flow
10.6B
↓ 5.79%
Investing Cash Flow
-2.4B
↓ 182.23%
Financing Cash Flow
-10.1B
↓ 25.1%
FY22Y/Y Change
Operating Cash Flow
9.0B
↓ 6.9%
Investing Cash Flow
-10.7B
↑ 393.64%
Financing Cash Flow
1.0B
↓ 110.84%
FY23Y/Y Change
Operating Cash Flow
8.6B
↓ 8.58%
Investing Cash Flow
-2.0B
↓ 81.82%
Financing Cash Flow
-7.1B
↓ 785.42%
Q2 FY23Q/Q Change
Operating Cash Flow
1.7B
↑ 2366.04%
Investing Cash Flow
-1.2B
↑ 136.27%
Financing Cash Flow
39.1M
↓ 109.75%
Q3 FY23Q/Q Change
Operating Cash Flow
2.7B
↑ 69.24%
Investing Cash Flow
-609.4M
↓ 49.07%
Financing Cash Flow
-2.2B
↓ 5783.87%
Q4 FY23Q/Q Change
Operating Cash Flow
1.2B
↓ 57.55%
Investing Cash Flow
339.3M
↓ 154.58%
Financing Cash Flow
-1.3B
↓ 43.87%
Q1 FY24Q/Q Change
Operating Cash Flow
1.1B
↓ 6.07%
Investing Cash Flow
-189.4M
↓ 155.6%
Financing Cash Flow
-1.7B
↑ 32.86%

Technicals Summary

Sell

Neutral

Buy

Gsk Plc-spon Adr. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
-11.32%
-26.39%
-4.26%
-34.71%
-38.74%
Eli Lilly And Company
Eli Lilly And Company
-17.51%
-6.6%
26.02%
187.94%
545.37%
Johnson & Johnson
Johnson & Johnson
-4.86%
1.3%
3.1%
-2.63%
12.62%
Merck & Co. Inc.
Merck & Co. Inc.
-6.36%
-23.83%
-1.79%
22.32%
16.86%
Novo Nordisk A/s
Novo Nordisk A/s
-11.88%
-23.43%
-0.61%
84.54%
276.9%
Abbvie Inc
Abbvie Inc
-9.02%
7.59%
24.02%
48.49%
99.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
21.66
21.66
0.71
3.95
0.22
0.07
0.05
3.43
Eli Lilly And Company
Eli Lilly And Company
78.73
78.73
0.69
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc.
Merck & Co. Inc.
20.22
20.22
0.07
7.74
0.28
0.11
0.03
17.58
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.57
22.7
0.89
0.21
0.01
27.07
Abbvie Inc
Abbvie Inc
58.45
58.45
0.4
10.94
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gsk Plc-spon Adr.
Gsk Plc-spon Adr.
Buy
$68.0B
-38.74%
21.66
8.02%
Eli Lilly And Company
Eli Lilly And Company
Buy
$715.2B
545.37%
78.73
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
12.62%
25.45
16.74%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$246.5B
16.86%
20.22
19.23%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
276.9%
34.03
35.01%
Abbvie Inc
Abbvie Inc
Buy
$296.5B
99.57%
58.45
9.22%

Insights on Gsk Plc-spon Adr.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 7.36B → 8.01B (in $), with an average increase of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.17B → -58.0M (in $), with an average decrease of 52.5% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 26.0% return, outperforming this stock by 30.3%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 187.9% return, outperforming this stock by 222.6%

Institutional Holdings

  • Dodge & Cox

    3.34%

  • FMR Inc

    1.42%

  • JTC Employer Solutions Trustee Ltd

    1.00%

  • Morgan Stanley - Brokerage Accounts

    0.99%

  • Fisher Asset Management, LLC

    0.91%

  • PRIMECAP Management Company

    0.73%

Corporate Announcements

  • Gsk Plc-spon Adr. Dividends March,2024

    In the quarter ending March,2024. Gsk Plc-spon Adr. has declared dividend of $0.41

    Read More

Company Information

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.

Organization
Gsk Plc-spon Adr.
Employees
70212
CEO
Ms. Emma Natasha Walmsley
Industry
Health Technology

FAQs